Prevalence of Chronic Pruritus in Germany: Results of a Cross-Sectional Study in a Sample Working Population of 11,730

Ständer, Sonja; Schäfer, Ines; Phan, Ngoc Quan; Blome, Christine; Herberger, Katharina; Heigel, H; Augustin, Matthias

doi:10.1159/000319862

Cited by 174 publications

(155 citation statements)

References 32 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…However, this study did not differentiate between acute (AP) and chronic pruritus (CP, defined as pruritus lasting 6 weeks and longer [2,3]) and was also limited by the fact that it was conducted in a single city. More recent studies analysing the prevalence of CP in Germany have revealed an even higher prevalence than expected and showed a point prevalence of 13.5% in the general population (4) and 16.8% in working adults (5).…”

mentioning

confidence: 87%

Prevalence and Characteristics of Pruritus: A One-Week Cross-sectional Study in a German Dermatology Practice

Kopyciok¹,

Ständer²,

Osada³

et al. 2016

Acta Derm Venerol

View full text Add to dashboard Cite

Pruritus is a frequent sensation in dermatoses, but its prevalence in patients in dermatological practices has not been fully studied. The aim of this cross-sectional study is to investigate its prevalence and characteristics in all patients attending a dermatology practice in Germany over a period of one week (n = 334; 52.7% female; median age 45.0 years). The point prevalence of pruritus in this study population was 36.2% (87.6% of whom had chronic pruritus). It inhibited the everyday life of 73.6% of all patients, with 77.7% reporting a frequently to permanently experienced moderate intensity. (5.2 ± 2.3 on the numerical rating scale). Of the patients, 52.1% had previously consulted their general practitioner, and 62% had visited the dermatologist due to pruritus. This study shows that pruritus is a highly prevalent, clinically and economically relevant symptom in dermatological practices. The majority of patients suffering from chronic pruritus are severely burdened and medically underserved. Dermatologists should be aware that pruritus also occurs frequently in patients who do not primarily present due to their symptoms.

show abstract

mentioning

confidence: 87%

Prevalence and Characteristics of Pruritus: A One-Week Cross-sectional Study in a German Dermatology Practice

Kopyciok¹,

Ständer²,

Osada³

et al. 2016

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…The German study showed that prevalence increased with age from 12.3% (16∼30 years) to 20.3% (61∼70 years) 6 . According to a Turkish study with 4,099 elderly dermatological patients, 11.5% reported pruritus, whereas the highest prevalence was in patients older than 85 years 8 .…”

Section: Frequency Of Chronic Pruritusmentioning

confidence: 99%

“…In a German pilot study a life-time prevalence of 22.6% was surveyed 5 . A recent cross-sectional observational study in ＞11,000 employees of 144 German companies demonstrated a point prevalence of 17% among German employees 6 . A quarter of the affected persons had suffered from pruritus for more than 5 years.…”

Section: Frequency Of Chronic Pruritusmentioning

confidence: 99%

Chronic Pruritus: Clinics and Treatment

Grundmann

Ständer

2011

Ann Dermatol

View full text Add to dashboard Cite

Chronic pruritus, one of the main symptoms in dermatology, is often intractable and has a high impact on patient's quality of life. Beyond dermatologic disorders, chronic pruritus is associated with systemic, neurologic as well as psychologic diseases. The pathogenesis of acute and chronic (＞6 weeks duration) pruritus is complex and involves in the skin a network of resident (e.g., sensory neurons) and transient inflammatory cells (e.g., lymphocytes). In the skin, several classes of histamine-sensitive or histamine-insensitve C-fibers are involved in itch transmission. Specific receptors have been discovered on cutaneous and spinal neurons to be exclusively involved in the processing of pruritic signals.Chronic pruritus is notoriously difficult to treat. Newer insights into the underlying pathogenesis of pruritus have enabled novel treatment approaches that target the pruritusspecific pathophysiological mechanism. For example, neurokinin-1 antagonists have been found to relieve chronic pruritus. (Ann Dermatol 23(1) 1∼11, 2011)

show abstract

“…The prevalence of chronic pruritus lasting over 6 weeks is about 20 % in the general population [1][2][3]. Diagnostics include the clarification of possible causes, such as diabetes, renal, hepatic or hematologic diseases or infections.…”

Section: Indications For Magistral Formulas In Pruritusmentioning

confidence: 99%

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Staubach¹,

Metz

2013

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryPruritus is a common symptom encountered by many different specialties. One must clinically differentiate between pruritus associated with skin disease or inflammation and pruritus with normal skin. Searching for possible underlying diseases is indispensable, because pruritus can be very chronic and has multiple pathogenetic mechanisms. Therapy -especially topical therapy -is difficult and often not successful. Very often systemic treatment has to be combined with topical approaches, considering both the active ingredients and appropriate vehicles. There are still open therapeutic gaps in the pharmaceutical product market, which can partially be resolved by using standard prescriptions for formulations. Due to the new pharmacy practice order, standardized compounded formulations should be given preference, since individual formulations often do not pass the plausibility check of the compounding pharmacist. Also the use of cosmetic ingredients (by example, commercial cold creams) is no longer permitted, since only ingredients with pharmaceutical quality can be used in compounding. We will show -based on practical cases -different therapeutic options for treatment with standardized magistral formulations from the NRF (New German Pharmacopoeia for compounded medications). Systemic and topical therapeutic agents complement each other in their efficacy. Causal and symptomatic therapies result in the most diverse therapeutic options since pruritus has so many causes. In many scenarios, novel therapeutic approaches or special vehicles require magistral formulas [4,5]. The new Pharmacy Practice Act requires a plausibility check of each prescription since 2012, so that frequently individual formulations are scrutinized, so that therapeutic alternatives in the form of magistral formulas are very welcome. We will present only established magistral formulas of the NRF that have already undergone a plausibility check [6,7]. Petra

show abstract

Prevalence of Chronic Pruritus in Germany: Results of a Cross-Sectional Study in a Sample Working Population of 11,730

Cited by 174 publications

References 32 publications

Prevalence and Characteristics of Pruritus: A One-Week Cross-sectional Study in a German Dermatology Practice

Prevalence and Characteristics of Pruritus: A One-Week Cross-sectional Study in a German Dermatology Practice

Chronic Pruritus: Clinics and Treatment

Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?

Contact Info

Product

Resources

About